ArticleFrontiers in cardiovascular medicine2026
Single-cell RNA sequencing pseudobulk analysis and machine learning identify candidate biomarkers for ischemic cardiomyopathy.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic cardiomyopathy (ICM) is a condition characterized by inadequate blood supply to the coronary arteries, resulting in myocardial damage and decreased cardiac functionality. This study aimed to identify potential biomarkers and regulatory networks in ICM, providing a foundation for further mechanistic and therapeutic investigations. Methods: We analyzed public single-cell RNA sequencing (scRNA-seq) data to identify cell subpopulations through dimensionality reduction clustering followed by manual annotation. Differentially expressed genes (DEGs) were derived using the pseudobulk method. Subsequently, we employed three machine learning algorithms combined with the Boruta feature selection approach to screen for disease-characteristic genes in an external ICM dataset. Potential regulatory networks were reconstructed by predicting transcription factors (TFs) and microRNAs (miRNAs). Finally, we validated the expression levels of signature genes, TFs, and miRNAs in an Results: The pseudobulk analysis identified 168 DEGs, with machine learning selecting four hub genes as key signatures demonstrating acceptable ICM discriminative power. Their area under the curve (AUC) values were as follows: MLLT3 (76.7%), GFOD1 (78.6%), COLEC12 (77.8%), and RARRES1 (79.9%). Notably, when combined into a four-gene signature, a substantially higher AUC of 93.0% was achieved for the discrimination of ICM. Transcription factor analysis delineated that GFOD1, MLLT3, RARRES1, and COLEC12 were regulated by 17, 7, 7, and 3 TFs, respectively. The CTCF was found to be a shared transcription factor. Computational miRNA analysis retrieved 329 miRNAs. Conclusion: Our study characterized GFOD1, MLLT3, COLEC12, RARRES1, miR-195-5p, and miR-5680 as promising biomarkers for ischemic cardiomyopathy, with CTCF acting as a candidate transcription factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.